<DOC>
	<DOCNO>NCT01520558</DOCNO>
	<brief_summary>This multi-center , open-label , non-controlled , non-randomized dose-escalating Phase 1 clinical study design examine safety infuse escalate dos CNDO-109-Activated Allogeneic Natural Killer Cells- ( first second degree relative ) , preparatory chemotherapy regimen , adult patient acute myeloid leukemia ( AML ) first complete remission time enrollment , candidate stem cell transplant , consider high risk recurrence .</brief_summary>
	<brief_title>CNDO-109-AANK AML First Complete Remission ( CR1 )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . The patient pathologically document AML CR1 time screen visit 2 . The patient achieve CR1 within 10 week screen visit ; patient may receive postremission consolidation therapy ( except transplant ) prior screen visit 3 . A bone marrow aspiration perform within 21 day prior start preinfusion preparative therapy confirm patient CR1 4 . The patient either refuse consider appropriate immediate candidate transplantation consider high risk recurrence least one follow prognostic factor : High risk cytogenetics ( 5 , 7 , del ( 5q ) , abnormal 3q , 11q23 translocation , complex cytogenetics ) cytogenetics normal presence FLT3 mutation without NPM1 mutation Age &gt; 60 year Antecedent hematological disorder ( AHD ) AML consider therapyrelated FAB subtype M0 ( minimally differentiate acute myeloblastic leukemia ) , M6 ( acute erythroid leukemia , include erythroleukemia ( M6a ) pure erythroid leukemia ( M6b ) ) , M7 ( acute megakaryoblastic leukemia ) 5 . The patient male female , age 18 year old 6 . The patient ECOG performance status 0 , 1 , 2 7 . The patient available NK cell donor HLA haploidentical firstdegree ( parent , child , sibling ) seconddegree ( child sibling ) relative ; minimum testing HLAA , HLAB , HLADR donor match 3/6 , 4/6 5/6 antigen 8 . The patient absence coexist medical problem would significantly increase risk chemotherapy procedure ( e.g . poor leave ventricular ejection fraction [ LVEF &lt; 40 % ] ) 9 . The patient recover reversible toxicity prior therapy . Permanent stable side effect change acceptable ≤ Grade 1 ( CTCAE , v4.03 ) 10 . The patient serum creatinine &lt; 2×ULN rise least 24 week chemotherapy . If elevate , 24hour creatinine clearance must &gt; 50 mL/min 11 . The patient serum total bilirubin &lt; 2 g/dL ( unless patient diagnosis Gilbert 's disease ) , SGOT ( ALT ) &lt; 3.5×ULN , SGPT ( AST ) &lt; 3.5×ULN 12 . The patient absolute neutrophil count ( ANC ) ≥1000/µL , platelet ≥100,000/µL transfusion dependent platelet and/or red cell 13 . The patient LVEF ≥40 % ECHO MUGA scan clinically significant abnormality 12lead ECG 14 . The patient PT ( INR ) PTT 1.25×ULN 15 . The patient must dependent supplemental oxygen 16 . The patient use effective contraceptive ( per institutional standard ) , procreative potential exist 17 . The patient must willing able comply study protocol requirement . The patient legally authorize representative must fully understand element informed consent sign informed consent accord institutional federal regulatory requirement 18 . The patient receive investigational chemotherapy within last 28 day prior screen visit never receive investigational immunotherapy . In addition , patient must receive treatment AML ( include treatment IL2 IFNγ ) interval time screen visit initiation preinfusion preparative therapy 1 . The patient previous bone marrow stem cell transplant 2 . The patient seropositive HIV 1 , HIV 2 , HBV , HCV 3 . The patient psychiatric , addictive , neurological disorder compromise ability give inform consent comply study requirement 4 . The patient pregnant ( confirm urine serum pregnancy test ) lactate 5 . The patient recently diagnose active malignancy require therapy 6 . The patient uncontrolled infection , receive antifungal treatment ongoing infection 7 . The patient know hypersensitivity bovine proteins 8 . The patient condition place patient undue risk discomfort result adherence study procedures 9 . The patient require treatment corticosteroid dose &gt; 0.1 mg/kg/day know allergy DSMO</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>High Risk Relapse</keyword>
	<keyword>Complete Remission</keyword>
	<keyword>Allogeneic Natural Killer Cells</keyword>
</DOC>